



University of Michigan
Medical School

Using Task Group 137 to Prescribe and Report Dose

Vrinda Narayana

The Department of Radiation Oncology
University of Michigan



University of Michigan
Medical School

TG137

- **AAPM Recommendations on Dose Prescription and Reporting Methods for Permanent Interstitial Brachytherapy for Prostate Cancer**

R. Nath
W. S. Bice
W. M. Butler
Z. Chen
A. Meigooni
V. Narayana
M. J. Rivard
Y. Yu




TG 137 Charge

- **Review**
 - **Prescription**
 - **Reporting**
 - **Radiobiological models**
- **Consensus**
 - **Min requirements for prescription and reporting**
 - Pre implant
 - Post implant
- **Recommend**
 - **Optimal requirements for prescription and reporting**
 - Pre implant
 - Post implant

Outline

Permanent Prostate Implants

- **Impact of dose reporting based upon**
 - Imaging modalities
 - Timing of imaging study
 - Treatment planning approaches
 - Interoperative planning strategies
- **Biophysical models**
 - BED
 - EUD
 - TCP



- Nomogram**

Table 1. Nomogram for monotherapy (125 Gy) using NASI MED3633 ^{103}Pd seed

Implant Volume (cc)	Average Dimension (cm)	Total Activity (U)	No. of Seeds (1.6 U/seed)	No. of Seeds (1.8 U/seed)	No. of Seeds (2.0 U/seed)
15	2.5	98	62	55	49
20	2.7	110	69	62	55
22	2.8	115	72	64	58
24	2.9	121	76	68	61
26	3.0	127	80	71	64
28	3.0	133	84	74	67
30	3.1	140	88	78	70
32	3.2	146	92	82	73
34	3.2	153	96	85	77
36	3.3	161	101	90	81
38	3.3	168	105	94	84
40	3.4	176	110	98	88
42	3.5	184	115	103	92
44	3.5	193	121	108	97
46	3.6	202	127	113	101
48	3.6	211	132	118	106
50	3.7	220	138	123	110
55	3.8	245	154	137	123


based on a modified peripheral
loading

Zheng *et al.*, Medical Dosimetry, **28**, 185 - 188 (2003).




University of Michigan
Medical School

History Dose Reporting



D_{99} – Dose to 99% of target
mPD – minimum Peripheral Dose

US PROSTATE DVH





Plan evaluation today


- **V100**
 - Vol that receives 100% of dose
 - 90 % excellent implant
- **D90**
 - Dose to 90 % of the volume
 - Prescribed dose



University of Michigan
Medical School

Today

- D_{90} – Dose to 90% of target
- V_{100} – Volume that receives Rx dose






- Dose calculation
- Imaging



University of Michigan
Medical School

Today



- D_{90} – Dose to 90% of target
- V_{100} – Volume that receives Rx dose





University of Michigan
Medical School

D90 issue



MR prostate

Impact of Imaging Modality on Dose Reporting







- **Ultrasound Imaging**
- **CT Imaging**
- **MR Imaging**
- **Recommendations on Imaging modality**



University of Michigan
Medical School

Imaging modalities


- Target delineation







University of Michigan
Medical School

Prostate Anatomy





Imaging Modalities


	Plane films	CT	MRI	TRUS
* Identification	+++	+	-	--
* Localization	+	++	0	--
Prostate Delineation	--	+	++	+
Critical St Delineation	--	+	++	0
Comfort	+	+	-	--
Cost & Convenience	++	-	--	+



University of Michigan
Medical School

Ultrasound








- Prostate
- Urethra
- Rectal wall





University of Michigan
Medical School


Ultrasound Apex / GUD Transition





University of Michigan
Medical School

MRI Coronal vs. CT Coronal





University of Michigan
Medical School

MR Anatomy

- Prostate
- Urethra
- Rectal wall
- Corpus
Cavernosum
- Pudendal Arteries
- Sphincter
- Neurovascular
bundle







CT Prostate

- **Apex – when do you stop**
- **Base – bladder neck obliteration**




University of Michigan
Medical School









University of Michigan
Medical School

Intra - lumen bladder density-small gland







University of Michigan
Medical School





University of Michigan
Medical School

Bladder Neck Obliteration





University of Michigan
Medical School



MRI Coronal vs. CT Coronal





University of Michigan
Medical School

MRI Coronal vs. CT Coronal





CT Prostate – post implant

- **Apex – when do you stop**
- **Base – bladder neck obliteration**
- **Seminal vesicles**
- **Rectal surface**




University of Michigan
Medical School

Axial CT
without Contour



Axial CT
with Contour



Axial MRI
without Contour



Axial MRI
with Contour






University of Michigan
Medical School


Variations without a Standard (Lee)

Observer 1




Vol	39 cc
D90	142 Gy
V100	93%

Observer 2



	48 cc
	123 Gy
	86%

Observer 3




	32 cc
	155 Gy
	99%





University of Michigan
Medical School

Perils of CT contouring



McLaughlin et. al.

- Prostate
- Outer Rectum
- Inner Rectum – de-expansion 5 mm
- Urethra – Foley
- Penile Bulb





University of Michigan
Medical School







Why MR? EXPECT VARIATION





University of Michigan
Medical School

CT contouring / 6 national experts








University of Michigan
Medical School

CT contouring

Wide margin implants




Narayana et. al.



University of Michigan
Medical School


Deviation from a Standard (6 experts)

MRI




36cc

Observer 1



34cc

Observer 2



38cc

Prostate Volume Agreement






University of Michigan
Medical School

Deviation from a Standard (6 experts)


MRI

Observer 1


Observer 2



148 Gy



153 Gy



143 Gy

D90 Agreement






University of Michigan
Medical School

Deviation from a Standard (6 experts)


MRI

Observer 1


Observer 2



95%




98%





92%

V100 Agreement





Prostate side view: Note labels on right. Prostate is not enlarged and does not extend into the bladder. Urethra opening from the bladder is open (yellow arrow). Sphincter is normal length and there is no bony restriction – note space between the bone and prostate (purple arrows)





normal prostate - normal appearance with light peripheral zone where tumors form and the dark central area called the transition zone – this enlarges with age



University of Michigan
Medical School

Multiparameter Imaging



- T2
- DCE
- DWI



Right side of the gland panel is normal prostate with clear PZ and TZ. On the left side (red) note the dark area that extends into the TZ and from front to back. This is tumor





Ur




with contrast the area of concern on the left side of the panel is clearly seen, with a suggestion of extension beyond the gland (arrow).

Uni



Note the tumor on the left side of the panel (red) and possible extension beyond the capsule

Imaging Recommendations



- **CT – 2/3 mm cuts**
- **Prostate – mindful of pitfalls**
- **Rectum outer – 1 cm sup and inf**
- **Rectal wall - 0.5 cm contraction**
- **Urethra**
 - **Foley Day 0**
 - **Foley Optional later scans**
- **Penial Bulb**



Imaging Guidelines MR

- **T2 3 mm cuts (no rectal coil)**
 - immediately before or after CT
 - Axial, coronal, sagittal
- **Rectum – 1 cm above & below**
- **Bladder – axial MR**
- **Urethra – axial and Sag MR**
- **Register CT-MR around prostate only**
- **CT – seed positions**



Impact of timing of imaging on dose reporting

- Prostate edema
- Source displacement with time
- Optimal timing for post implant dosimetry
- Recommendations on timing of imaging




Edema

- ? **Needle insertion**
- ? **Bleeding – needle penetration**
- ? **General inflammation**



Edema Model





Edema Model

? T max


? Different imaging modalities

? Prostate Volumes



University of Michigan
Medical School

Edema




Narayana et. al.



University of Michigan
Medical School

Edema




McLaughlin et. al



University of Michigan
Medical School

MR edema



Chung et. al



Edema Model

- **Max – 1 day**
- **Longer to resolve than initial swelling**
- **Quick resolution - 2 weeks**
- **Slow resolution – 2 to 4 weeks**
- **$T_{1/2} \sim 10$ d (4 to 25 days)**



Effect on post implant dosimetry

- **Day 1 – edema large**
 - underestimate dose
- **Day 100 – edema resolved**
 - overestimate dose

- **Assumes seeds move with the prostate**
 - Seeds inside the prostate
- ? **Stranded seeds**



University of Michigan
Medical School



McLaughlin et. al.




University of Michigan
Medical School






University of Michigan
Medical School






University of Michigan
Medical School





University of Michigan
Medical School



By how much?

- Timing of imaging
- Magnitude of prostate swelling
- Rate of resolution
- Radioactive $T_{1/2}$
 - ↑ Short $T_{1/2}$ & low energy

Optimal time

- ^{131}Cs $10_{\pm 2}$ days
- ^{103}Pd $16_{\pm 2}$ days
- ^{125}I $42_{\pm 2}$ days



Recommendation Timing of imaging

- **Pre-Implant prostate volume**
- **Implant day dosimetry**
 - US immediate
 - CT/MR 2 to 4 h
- **Post-Implant dosimetry**
 - ^{131}Cs 10 \pm 2 days
 - ^{103}Pd 16 \pm 2 days
 - ^{125}I 1month \pm 1week

The optimal timing for post implant dosimetry is

20% 1. Immediately following the implant

20% 2. 2 weeks after the implant

20% 3. 1 month after the implant

20% 4. 10, 16 and 42 days for ^{131}Cs , ^{103}Pd , ^{125}I

20% respectively

5. No post implant dosimetry is required

The optimal timing for post implant dosimetry is

- 20% 1. Immediately following the implant
- 20% 2. 2 weeks after the implant
- 20% 3. 1 month after the implant
- 20% 4. 10, 16 and 42 days for ^{131}Cs , ^{103}Pd , ^{125}I
- 20% respectively
- 5. No post implant dosimetry is required

Answer: 4

Reference: AAPM TG137, Nath et. al. 2009

Post implant prostate volume under- or overestimation is a result of

- 20% 1. The timing of dosimetry
- 20% 2. Magnitude of preimplant prostate swelling
- 20% 3. The rate of edema resolution
- 20% 4. The radioactive decay half-life
- 20% 5. All of the above

Post implant prostate volume under- or overestimation is a result of

- 20% 1. The timing of dosimetry
- 20% 2. Magnitude of preimplant prostate swelling
- 20% 3. The rate of edema resolution
- 20% 4. The radioactive decay half-life
- 20% 5. All of the above

Answer: 5

Reference: AAPM TG137, Nath et. al. 2009


Impact of treatment planning approaches on dose reporting

- **Planning techniques**
- **Choice of isotope**
- **Choice of source strength**
- **Calculation Algorithm**
- **Dose indices for target and normal tissue**
- **Recommendations for planning and dose reporting**




University of Michigan
Medical School



Peripheral loading?



Prostate, with error



Prostate + 0.5 cm margin, with error



Loose seeds vs strands

- **Loose Seeds**



Expand with the prostate



Migrate to the lung

- **Strands**



No migration



May not track with the prostate

Seed Drop off

- **Stranded preloaded**
- **Mick applicator**
- **Thin stranded seeds**
- **Preloaded cartridge**



University of Michigan
Medical School

Seed Drop off

	Rapid Strand	Mick applicator	Thin strand	Preloaded cartridge
Prostate V100 %	96.5 \pm 2	93.2 \pm 5	93.4 \pm 4	94.1 \pm 3
Prostate D90 Gy	109 \pm 7	102 \pm 19	106 \pm 17	101 \pm 8
Rec wall D1cc Gy	95 \pm 18	70.4 \pm 8	70 \pm 23	73 \pm 11
Rec wall D2cc Gy	59 \pm 17	53 \pm 18	52 \pm 18	54 \pm 10
Urethra D10 Gy	156 \pm 25	163 \pm 36	164 \pm 21	158 \pm 31



Choice of Isotope



- ^{131}Cs
- ^{103}Pd
- ^{125}I



University of Michigan
Medical School

I125

• I-125 vs. Pd-103





University of Michigan
Medical School


Seed Drop off

	Rapid Strand	Mick applicator	Thin strand	Preloaded cartridge
Prostate V100 %	96.5 \pm 2	93.2 \pm 5	93.4 \pm 4	94.1 \pm 3
Prostate D90 Gy	109 \pm 7	102 \pm 19	106 \pm 17	101 \pm 8
Rec wall D1cc Gy	95 \pm 18	70.4 \pm 8	70 \pm 23	73 \pm 11
Rec wall D2cc Gy	59 \pm 17	53 \pm 18	52 \pm 18	54 \pm 10
Urethra D10 Gy	156 \pm 25	163 \pm 36	164 \pm 21	158 \pm 31




Source strength?

- **Prospective Randomized Trial**
 - high vs. low mCi
 - No sig diff



Narayana et. al



Axial



University of Michigan
Medical School

Calculation Algorithm



Recommendations

- GTV
- CTV – no posterior expansion
- PTV=CTV
- OAR
 - Urethra
 - Rectum
 - Penile bulb



Recommendations

- **Dose clinical decision**
 - **^{131}Cs 115 Gy ? (100-125 Gy)**
 - **^{103}Pd 125 Gy**
 - **^{125}I 145 Gy**



Recommendations Planning criteria

- **CTV**
 - $V100 > 95\%$ of CTV
 - $D90 > 100\%$ of Rx
 - $V150 < 50\%$ of CTV
- **Rectum $D2cc < Rx$ dose**
- **Urethra**
 - $D10 < 150\%$ Rx dose
 - $D30 < 130\%$ of Rx dose
- **Penile bulb - investigational**



Recommendations Dose Reporting

- **DVH for target**
 - **Primary, D90,V100, V150**
 - **Secondary V200, V90,D100**
- **Urethra – D10**
 - **Secondary: D0.4cc, D30, D5**
- **Rectum – D2cc,**
 - **Secondary: D0.1 cc, V100**

Primary dose parameters for prostate implant that should always be reported are

20%

1. D_{90}

20%

2. V_{100}

20%

3. D_{90} & V_{150}

20%

4. D_{90} V_{100} & V_{150}

20%

5. D_{90} D_{100} V_{90} V_{100} & V_{150}

Primary dose parameters for prostate implant that should always be reported are

20%

1. D_{90}

20%

2. V_{100}

20%

3. D_{90} & V_{150}

20%

4. D_{90} V_{100} & V_{150}

20%

5. D_{90} D_{100} V_{90} V_{100} & V_{150}

Answer: 4

Reference: AAPM TG137, Nath et. al. 2009



Intraoperative treatment planning strategies

- **Intraoperative preplanning**
- **Interactive planning**
- **Dynamic dose calculations**
- **Recommendations on Intraoperative planning and evaluation**

Pre vs. OR planning

Pre

- 🙄 2 procedures
- 🙄 Reproducible setup
- 😄 Time pressure
- 😄 # of seeds ordered

OR

- 😄 Target Volume
- 🙄 Stress

Techniques

- **Intraoperative**
 - Creation of plan in OR just before the implant
 - Immediate execution
- **Interactive**
 - Stepwise refinement
 - Computerized dose calculations based on image feedback
- **Dynamic**
 - Calculations constantly updated using continuous deposited-seed-position feed back

Recommendations

- **Enhanced implant quality**
- **Post implant dosimetry**
 - **Edema**
 - **Seed migration**

- Research setting

- **BED for prostate implants**
- **EUD calculations**
- **TCP**
- **Recommendations for reporting radiobiological response**



$$BED = D[1 + D / (\alpha / \beta)]$$

$$BED = D(T_{eff}) RE(T_{eff}) - \ln 2 \frac{T_{eff}}{\alpha T_p}$$

$$RE(T) = 1 + \left(\frac{\beta}{\alpha}\right) \frac{\dot{D}_0}{(\mu - \lambda)} \times \frac{1}{1 - e^{-\lambda T_{eff}}} \left\{ 1 - e^{-2\lambda T_{eff}} - \frac{2\lambda}{\mu + \lambda} (1 - e^{-(\mu + \lambda) T_{eff}}) \right\}$$

$$T_{eff} = T_{avg} \ln \left[\alpha \cdot D \cdot \frac{T_p}{T_{1/2}} \right]$$



BED for inhomogeneous dose

$$BED = -\frac{1}{\alpha} \ln\left(\sum_i v_i e^{-\alpha \cdot BED_i}\right)$$

$$D(T_{eff}) RE(T_{eff}) - \ln 2 \frac{T_{eff}}{\alpha T_p} = -\frac{1}{\alpha} \ln\left(\sum_i v_i e^{-\alpha \cdot BED_i}\right)$$



Equivalent uniform EBRT dose

$$EUD_d = \frac{-\ln(\sum_i v_i e^{-\alpha \cdot BED_i})}{\alpha + \beta d - \gamma \ln 2 / (d \cdot T_p)}$$



TCP

$$TCP(D) = \frac{1}{1 + (TCD_{50} / D)^k}$$

$$TCP = \exp[-N_0 \exp(-\alpha \cdot BED)]$$



Example

<u>Indices</u>	Radionuclide		
	^{125}I	^{103}Pd	^{131}Cs
Dose (Gy)	145.0	125.0	120.0
BED (Gy)	110.9	115.4	117.3
EUD (Gy)	69.7	72.6	73.8
TCP (%)	74.1	85.9	89.2
T_{eff} (day)	235.3	93.9	60.8

Calculated with: $\alpha = 0.15 \text{ Gy}^{-1}$, $\beta = 0.05 \text{ Gy}^{-2}$, $\alpha/\beta = 3.0 \text{ Gy}$, $T_p = 42$ days, repair half-life of 0.27 hour, and $N_0 = 5 \times 10^6$



Linear Quadratic Model

$$ERD = Nd \left[1 + \frac{d}{\alpha/\beta} \right]$$

- **N = # fx**
- **D = dose/fx**
- **$\alpha/\beta = 3\text{Gy}$**



Linear Quadratic Model

$$ERD = NRt \left[1 + G \frac{Rt}{\alpha/\beta} \right]$$

- **R = dose rate**
- **t = time**



Linear Quadratic Model

$$G_{LDR} = \frac{2}{\mu t} \left[1 - \frac{(1 - e^{-\mu t})}{\mu t} \right]$$

- μ = repair rate const

$$ERD = NRt \left[1 + G \frac{Rt}{\alpha/\beta} \right]$$



Linear Quadratic Model

$$ERD_{IMP} = R / \lambda \left[1 + \frac{R}{(\mu + \lambda)\alpha / \beta} \right]$$

- **R = dose rate**
- **λ = decay constant**
- **μ = repair rate constant**
- **α/β = tissue specific parameter**



Linear Quadratic Model

0.625

- Beam ?

- $d = 2 \text{ Gy/fx}$
- $\alpha/\beta = 3\text{Gy}$

$$ERD = D_{eq} \left[1 + \frac{d}{\alpha/\beta} \right]$$

- Brachy

- $R = 4.4 \text{ cGy/h}$
- $\lambda = 0.693/59.4 \text{ d}^{-1}$
- $\alpha/\beta = 3\text{Gy}$
- $\mu = .4 \text{ h}^{-1}$

$$ERD = R / \lambda \left[1 + \frac{R}{(\mu + \lambda)\alpha/\beta} \right]$$

- Adequate information
 - BED
 - EUD
 - TCP
 - Other



Recommendation

- **Model parameters should be specified**
- **All parameters required to calculate the biodose should be specified**
- **Encourage vendors to provide models**

What is the cause of most inconsistencies in dose reporting?

20% 1. Identification of source positions

20% 2. Dose calculations

20% 3. Target delineation

20% 4. Timing of the imaging study

20% 5. Type of isotope used

What is the cause of most inconsistencies in dose reporting?

20% 1. Identification of source positions

20% 2. Dose calculations

20% 3. Target delineation

20% 4. Timing of the imaging study

20% 5. Type of isotope used

Answer: 3

Reference: AAPM TG137, Nath et. al. 2009